Mentions
Extended reach
Total likes
Video views
AI synopsis
The summary reflects a shared recognition of the trial's importance, with examples like references to neurological dysfunction being more common with cefepime and mentions of the study’s presentation at major conferences. The tone is professional and focused on clinical implications, demonstrating high engagement and interest in evidence-based practice changes.
Most discussions support the findings, emphasizing that the study shows no significant difference in kidney injury risk and highlights increased neurological issues with cefepime, indicating general agreement with the publication's conclusions.
Participants demonstrate high interest by referencing multiple presentations, the clinical significance of findings, and ongoing debates about antibiotic safety, signaling strong engagement with the topic.
The discussions include summaries of trial results, links to the publication, expert opinions, and considerations for changing clinical practice, reflecting deep engagement.
The findings appear to influence clinical practice and research, evidenced by mentions of trial presentations, updates being trending, and calls for practice changes, indicating a high level of impact.
「バンコマイシン＋ゾシンは腎臓に悪い」がすっかり定着してしまいましたが、セフェピンと比較してゾシンは急性腎傷害を増やさないという結果。 セフェピンでせん妄や昏睡といった神経合併症が増えるかも。 ACORN trial https://t.co/OjA2BmNSW9
セフェピムといえば神経障害、タゾピペといえば腎障害の副作用。 この論文は直接比較してみた結果。 腎障害は有意差がなかったが、神経障害（せん妄、昏睡）はセフェピムの方が有意に多かった。 https://t.co/SQfyj6cBC4
Las personas que reciben Piperacilina/tazobactam tuvieron la misma Incidencia de lesión renal aguda o algún evento renal mayor (~25%), al comparar con cefepime. Este último tuvo mayores complicaciones neurológicas En ensayo clínico #ISNyoung JAMA 2023 10.1001/jama.2023.20583 https://t.co/xqYoKtRnek
「ゾシン vs. セフェピム」論争再燃か。 ACORN trialでは14日死亡率にも急性腎傷害（AKI）にも有意差はなく、意識障害はセフェピムの方が多いという結果だったけど、14日では短かったということ？ ACORN trial https://t.co/OjA2BmNSW9 https://t.co/BXuqGWwjXb
急性感染症の入院患者に対するCFPM vs TAZ/PIPCの非盲検 RCT（ACORN）がJAMAに出てました。 14日までの急性腎障害や死亡の複合アウトカムは有意差なし。 副次アウトカムではCFPMの方がせん妄や昏睡などの神経障害が多い結果だった。 https://t.co/G8rWftOatA
#UpdatesInHM 6: Cefepime vs. Pip-Tazo ACORN Trial https://t.co/WNmjch3Rfh PMID: 37837651
Diagnostic stewardship has become essential in clinical practice over the past decade, impacting patient care and public health. This episode discusses practical testing improvements, the role of AI, and how thoughtful…
CFPMは神経障害の可能性 Cefepime vs Piperacillin-Tazobactam in Adults Hospitalized With Acute Infection: The ACORN Randomized Clinical Trial - PubMed https://t.co/qlHqVchaAH
RT @ABsteward:
RT @PulmCrit: PIPERACILLIN-TAZOBACTAM IS NOT NEPHROTOXIC: exploring the arc of a myth over time this was clearly a myth in 2016: https://t…
RT @PulmCrit: PIPERACILLIN-TAZOBACTAM IS NOT NEPHROTOXIC: exploring the arc of a myth over time this was clearly a myth in 2016: https://t…
RT @nickmmark: #ACORN RCT just dropped: N=2511 adults hospitalized w/ acute infection randomized to cefepime vs pip-tazo. No difference i…
RT @ABsteward:
RT @ABsteward:
Do you use vanc and zosyn together? Or has the ACORN trial changed your mind? @JAMANetwork https://t.co/5zRjmM49AD
RT @PulmCrit: PIPERACILLIN-TAZOBACTAM IS NOT NEPHROTOXIC: exploring the arc of a myth over time this was clearly a myth in 2016: https://t…
https://t.co/SbubnWVjQz
Cefepime vs Piperacillin-Tazobactam in Adults Hospitalized With Acute Infection https://t.co/5BoIAWiCrc
Among hospitalized adults, the risk of acute kidney injury did not differ between cefepime and piperacillin-tazobactam, but neurological dysfunction was more common with cefepime. Note that 77.2% were receiving vancomycin at enrollment. @JAMA_current https://t.co/IHIhR1bbHA
Thank you to our very own Darla Fink, MD for presenting at our Pediatric Journal Club yesterday. Darla is our Chief Pediatric Critical Care Fellow. She presented: ACORN Trial: Cefepime vs Piperacillin-Tazobactam in Adults Hospitalized With Acute Infection. https://t.co/JrHVXG7goL
RT @ABsteward:
RT @infeccHRUmalaga: Ensayo clínico @JAMA_current Enfrenta #cefepime VS #PPZ/TZB
RT @ABsteward:
RT @yakuzaimori: セフェピムといえば神経障害、タゾピペといえば腎障害の副作用。 この論文は直接比較してみた結果。 腎障害は有意差がなかったが、神経障害（せん妄、昏睡）はセフェピムの方が有意に多かった。 https://t.co/SQfyj6cBC4
セフェピムといえば神経障害、タゾピペといえば腎障害の副作用。 この論文は直接比較してみた結果。 腎障害は有意差がなかったが、神経障害（せん妄、昏睡）はセフェピムの方が有意に多かった。 https://t.co/SQfyj6cBC4
RT @YukiKotani5: Cefepime vs piperacillin/tazobactam in acute infection: ACORN trial 2511 hospitalized pts prescribed antipseudomonal anti…
RT @PCCRG: Next up from the @PCCRG https://t.co/8dxjXzcqbP
RT @PCCRG: Next up from the @PCCRG https://t.co/8dxjXzcqbP
RT @PulmCrit: PIPERACILLIN-TAZOBACTAM IS NOT NEPHROTOXIC: exploring the arc of a myth over time this was clearly a myth in 2016: https://t…
RT @ryoma_tanaka: 「ゾシン vs. セフェピム」論争再燃か。 ACORN trialでは14日死亡率にも急性腎傷害（AKI）にも有意差はなく、意識障害はセフェピムの方が多いという結果だったけど、14日では短かったということ？ ACORN trial htt…
RT @ryoma_tanaka: 「ゾシン vs. セフェピム」論争再燃か。 ACORN trialでは14日死亡率にも急性腎傷害（AKI）にも有意差はなく、意識障害はセフェピムの方が多いという結果だったけど、14日では短かったということ？ ACORN trial htt…
RT @ryoma_tanaka: 「ゾシン vs. セフェピム」論争再燃か。 ACORN trialでは14日死亡率にも急性腎傷害（AKI）にも有意差はなく、意識障害はセフェピムの方が多いという結果だったけど、14日では短かったということ？ ACORN trial htt…
RT @ryoma_tanaka: 「ゾシン vs. セフェピム」論争再燃か。 ACORN trialでは14日死亡率にも急性腎傷害（AKI）にも有意差はなく、意識障害はセフェピムの方が多いという結果だったけど、14日では短かったということ？ ACORN trial htt…
RT @ryoma_tanaka: 「ゾシン vs. セフェピム」論争再燃か。 ACORN trialでは14日死亡率にも急性腎傷害（AKI）にも有意差はなく、意識障害はセフェピムの方が多いという結果だったけど、14日では短かったということ？ ACORN trial htt…
「ゾシン vs. セフェピム」論争再燃か。 ACORN trialでは14日死亡率にも急性腎傷害（AKI）にも有意差はなく、意識障害はセフェピムの方が多いという結果だったけど、14日では短かったということ？ ACORN trial https://t.co/OjA2BmNSW9 https://t.co/BXuqGWwjXb
RT @georgepapadapol: Esquema empírico con Cefepime Vs Pip-Tazo para pacientes hospitalizados con infección aguda: Resultados del ACORN Tria…
Esquema empírico con Cefepime Vs Pip-Tazo para pacientes hospitalizados con infección aguda: Resultados del ACORN Trial: #ATS2024 Sin diferencias en deterioro de función renal ni mortalidad, pero con cefepime más coma o delirio
RT @aaeminfo: Read the paper that they discussed, here: https://t.co/DhDwwWd7N3 Let us know your thoughts below!
Read the paper that they discussed, here: https://t.co/DhDwwWd7N3 Let us know your thoughts below!
In this month's CCMS-AAEM paper discussion, members focused on a paper titled, "Cefepime vs Piperacillin-Tazobactam in Adults Hospitalized With Acute Infection". Watch the Recorded Discussion: https://t.co/MLzrbtIsnJ
RT @serperm: @AnandVKulkarni2 @robertpdickson One of my recent favorite trials shared with me by @AshleySpannMD: prospective, pragmatic, a…
RT @serperm: @AnandVKulkarni2 @robertpdickson One of my recent favorite trials shared with me by @AshleySpannMD: prospective, pragmatic, a…
RT @serperm: @AnandVKulkarni2 @robertpdickson One of my recent favorite trials shared with me by @AshleySpannMD: prospective, pragmatic, a…
@AnandVKulkarni2 @robertpdickson One of my recent favorite trials shared with me by @AshleySpannMD: prospective, pragmatic, and randomized. No mortality difference between pip-tazo and cefepime. More neuro dysfunction with cefepime. https://t.co/WaWsUUP0bl
RT @SOCCA_CritCare: Check out the ACORN Trial from @JAMA_current evaluating the use of Cefepime and Zosyn and their risk of AKI and neurolo…
Check out the ACORN Trial from @JAMA_current evaluating the use of Cefepime and Zosyn and their risk of AKI and neurological dysfunction in treatment of hospitalized patients infection. https://t.co/olt2cT9kp9 What's your usual practice in regards to broad spectrum antibiotics? https://t.co/DihKG8TXEk
RT @drtimothyli: 5. Comparison of cefepime versus pip-tazo for adults hospitalized with acute infection showed similar risk for acute kidne…
5. Comparison of cefepime versus pip-tazo for adults hospitalized with acute infection showed similar risk for acute kidney injury, but neurologic dysfunction was more common with cefepime ⭐ACORN trial
The ACORN Trial: Among hospitalized adults, the risk of acute kidney injury did not differ between cefepime and piperacillin-tazobactam, but neurological dysfunction was more common with cefepime. #SHEASpring2024 https://t.co/B1TtyHp0G0
RT @JHospMedicine: #UpdatesInHM 6: Cefepime vs. Pip-Tazo ACORN Trial https://t.co/WNmjch3Rfh PMID: 37837651
RT @JHospMedicine: Wow! We learned so much! How about you?
RT @JHospMedicine: #UpdatesInHM 6: Cefepime vs. Pip-Tazo ACORN Trial https://t.co/WNmjch3Rfh PMID: 37837651
RT @JHospMedicine: Wow! We learned so much! How about you?
RT @JHospMedicine: Wow! We learned so much! How about you?
RT @JHospMedicine: Wow! We learned so much! How about you?
RT @JHospMedicine: Wow! We learned so much! How about you?
RT @JHospMedicine: Wow! We learned so much! How about you?
RT @JHospMedicine: Wow! We learned so much! How about you?
Wow! We learned so much! How about you?
RT @JHospMedicine: #UpdatesInHM 6: Cefepime vs. Pip-Tazo ACORN Trial https://t.co/WNmjch3Rfh PMID: 37837651
RT @JHospMedicine: #UpdatesInHM 6: Cefepime vs. Pip-Tazo ACORN Trial https://t.co/WNmjch3Rfh PMID: 37837651
RT @JHospMedicine: #UpdatesInHM 6: Cefepime vs. Pip-Tazo ACORN Trial https://t.co/WNmjch3Rfh PMID: 37837651
RT @JHospMedicine: #UpdatesInHM 6: Cefepime vs. Pip-Tazo ACORN Trial https://t.co/WNmjch3Rfh PMID: 37837651
RT @JHospMedicine: #UpdatesInHM 6: Cefepime vs. Pip-Tazo ACORN Trial https://t.co/WNmjch3Rfh PMID: 37837651
RT @JHospMedicine: #UpdatesInHM 6: Cefepime vs. Pip-Tazo ACORN Trial https://t.co/WNmjch3Rfh PMID: 37837651
RT @JHospMedicine: #UpdatesInHM 6: Cefepime vs. Pip-Tazo ACORN Trial https://t.co/WNmjch3Rfh PMID: 37837651
RT @JHospMedicine: #UpdatesInHM 6: Cefepime vs. Pip-Tazo ACORN Trial https://t.co/WNmjch3Rfh PMID: 37837651
#UpdatesInHM 6: Cefepime vs. Pip-Tazo ACORN Trial https://t.co/WNmjch3Rfh PMID: 37837651
Dr. Emily Montgomery, PGY-2 Emergency Medicine Pharmacy Resident from Tampa General Hospital, presented on "Cefepime vs Piperacillin-Tazobactam in Adults Hospitalized With Acute Infection: The ACORN Randomized Clinical Trial." https://t.co/RR9sKVEKbz
RT @ABsteward:
RT @ABsteward:
Cefepime vs Piperacillin-Tazobactam in Adults Hospitalized With Acute Infection: The ACORN Randomized Clinical Trial | Critical Care Medicine | JAMA | JAMA Network https://t.co/KxtThjokPl
RT @PulmCrit: PIPERACILLIN-TAZOBACTAM IS NOT NEPHROTOXIC: exploring the arc of a myth over time this was clearly a myth in 2016: https://t…
RT @ClaudioSandron3: In the ACORN randomised trial on 2511 adults with acute #infection in ED or ICU at enrollment, #Piperacillin_Tazobacta…
In the ACORN randomised trial on 2511 adults with acute #infection in ED or ICU at enrollment, #Piperacillin_Tazobactam (bolus + ext. infusion) was not associated with higher AKI rates vs. Cefepime (10.2 vs. 8.8%). https://t.co/G2bCckLre7 https://t.co/BxWu1IiWdz
Cefepime vs Piperacillin-Tazobactam in Adults Hospitalized With Acute Infection https://t.co/1FTzqNPNls
RT @WICSBottomLine: #TBL 443: ACORN - Cefepime vs Piperacillin-Tazobactam in Adults Hospitalized With Acute Infection https://t.co/R7muTUXb…
RT @WICSBottomLine: #TBL 443: ACORN - Cefepime vs Piperacillin-Tazobactam in Adults Hospitalized With Acute Infection https://t.co/R7muTUXb…
#TBL 443: ACORN - Cefepime vs Piperacillin-Tazobactam in Adults Hospitalized With Acute Infection https://t.co/R7muTUXbV9 Article by @EdQian Review b @hgmwalker89 #FOAMed #FOAMcc #Sepsis https://t.co/lB1xQIGwJc
RT @KBibbinsDomingo: Cefepime vs Piperacillin-Tazobactam in Adults Hospitalized With Acute Infection: The ACORN Randomized Clinical Trial…
RT @KBibbinsDomingo: Cefepime vs Piperacillin-Tazobactam in Adults Hospitalized With Acute Infection: The ACORN Randomized Clinical Trial…
#CPPPLU Highlights. The ACORN RCT published in @JAMA_current found no difference in incidence of AKI between piperacillin-tazobactam and cefepime when used as empiric therapy. Patients who received cefepime had ↑ neurologic dysfunction. #PharmICU https://t.co/p2NNlxiIql
RT @ABsteward:
RT @KBibbinsDomingo: Cefepime vs Piperacillin-Tazobactam in Adults Hospitalized With Acute Infection: The ACORN Randomized Clinical Trial…
RT @KBibbinsDomingo: Cefepime vs Piperacillin-Tazobactam in Adults Hospitalized With Acute Infection: The ACORN Randomized Clinical Trial…
RT @KBibbinsDomingo: Cefepime vs Piperacillin-Tazobactam in Adults Hospitalized With Acute Infection: The ACORN Randomized Clinical Trial…
RT @KBibbinsDomingo: Cefepime vs Piperacillin-Tazobactam in Adults Hospitalized With Acute Infection: The ACORN Randomized Clinical Trial…
RT @KBibbinsDomingo: Cefepime vs Piperacillin-Tazobactam in Adults Hospitalized With Acute Infection: The ACORN Randomized Clinical Trial…
Cefepime vs Piperacillin-Tazobactam in Adults Hospitalized With Acute Infection: The ACORN Randomized Clinical Trial - @EdQian @toddrice_ICU & colleagues jamanetwork.com/journals/jam... One of our
RT @KBibbinsDomingo: Cefepime vs Piperacillin-Tazobactam in Adults Hospitalized With Acute Infection: The ACORN Randomized Clinical Trial…
Cefepime vs Piperacillin-Tazobactam in Adults Hospitalized With Acute Infection: The ACORN Randomized Clinical Trial - @EdQian @toddrice_ICU & colleagues https://t.co/xA5SHNaUbT One of our
RT @IcuCast: Episode 26! A crossover episode with our pals at @PulmPEEPs! Thankful to them for giving us the opportunity to talk about the…
@AstridWeins @VelezNephHepato There’s also this trial https://t.co/SPKyuvQTK9 which helps solve the confounding by sepsis greatly (Though it cannot rule out rarer events of course) https://t.co/zXmBqhr1sO
RT @ABsteward:
RT @IcuCast: Episode 26! A crossover episode with our pals at @PulmPEEPs! Thankful to them for giving us the opportunity to talk about the…
RT @IcuCast: Episode 26! A crossover episode with our pals at @PulmPEEPs! Thankful to them for giving us the opportunity to talk about the…
RT @IcuCast: Episode 26! A crossover episode with our pals at @PulmPEEPs! Thankful to them for giving us the opportunity to talk about the…
RT @IcuCast: Episode 26! A crossover episode with our pals at @PulmPEEPs! Thankful to them for giving us the opportunity to talk about the…
Episode 26! A crossover episode with our pals at @PulmPEEPs! Thankful to them for giving us the opportunity to talk about the ACORN trial (cefepime vs pip-tazo) which was published in @JAMA_current by... us (Ed and Todd)! ACORN: https://t.co/iO7GoI1Bu0 https://t.co/qPyhTM3p2C https://t.co/a5784AqwOE
Cefepime vs Piperacillin-Tazobactam in Adults Hospitalized With Acute Infection https://t.co/FEDulqtbSt
RT @SCCM_CPP: Is there a difference in AKI risk and neurological dysfunction when using cefepime vs piperacillin-tazobactam? Check out the…
Is there a difference in AKI risk and neurological dysfunction when using cefepime vs piperacillin-tazobactam? Check out the ED Committee’s infographic by @kacyoldsen summarizing last month’s #SCCMJC #PharmICU https://t.co/p2NNlxiIql https://t.co/f4PGE5t2YX
RT @KBibbinsDomingo: Read the ACORN trial here #ESICM #LIVES2023 Cefepime vs Piperacillin-Tazobactam in Adults Hospitalized With Acute In…
Mark Your Calendars- Dr. Hanh Tran, PharmD, PGY1 Pharmacy Resident at Wellstar MCG Health, will present the ACORN trial: Cefepime vs piperacillin-tazobactam in adults hospitalized with acute infection. https://t.co/oKhfIVNWsV
RT @ABsteward:
RT @ABsteward:
RT @ABsteward:
RT @ABsteward:
RT @ABsteward:
RT @ABsteward:
@JamesWilsonDO1 @iddoctor @IdVilchez Not only does it happen but has major consequences for patients and is attributable to cefepime exposure NNH around 33 based on ACORN trial doi: 10.1001/jama.2023.20583 https://t.co/MGiHnrkiDu
New today: Cefepime vs Piperacillin-Tazobactam in Adults Hospitalized With Acute Infection https://t.co/suoIXuNrIV #CME
New from JN Learning: Cefepime vs Piperacillin-Tazobactam in Adults Hospitalized With Acute Infection https://t.co/oGDUgIbE0U
RT @taka33chan: TAZ/PIPCはCFPMに比べのAKIのrisk有意差なかったとのこと Cefepime vs Piperacillin-Tazobactam in Adults Hospitalized With Acute Infection https:…
RT @PulmCrit: PIPERACILLIN-TAZOBACTAM IS NOT NEPHROTOXIC: exploring the arc of a myth over time this was clearly a myth in 2016: https://t…
@SCCM @KiousenterlisN @nyphospital @ATSBlueEditor #SCCMJC #PharmICU Presenter 2: Kacy Oldsen, PharmD @kacyoldsen PGY2 CC @MyMemorial Cefepime vs Piperacillin-Tazobactam in Adults Hospitalized With Acute Infection (ACORN) @JAMA_current https://t.co/p2NNlxiIql
TAZ/PIPCはCFPMに比べのAKIのrisk有意差なかったとのこと Cefepime vs Piperacillin-Tazobactam in Adults Hospitalized With Acute Infection https://t.co/2kzMFL8iCD
It's world pneumonia day. Have you changed your clinical practice based on the ACORN study? https://t.co/XEEYQTZd6K #pneumoniaday #antibiotics #evidencebasedpractice
RT @SCCM_CPP: @SCCM @KiousenterlisN @nyphospital @ATSBlueEditor #SCCMJC #PharmICU Presenter 2: Kacy Oldsen, PharmD @kacyoldsen PGY2 CC @My…
@SCCM @KiousenterlisN @nyphospital @ATSBlueEditor #SCCMJC #PharmICU Presenter 2: Kacy Oldsen, PharmD @kacyoldsen PGY2 CC @MyMemorial Cefepime vs Piperacillin-Tazobactam in Adults Hospitalized With Acute Infection (ACORN) @JAMA_current https://t.co/p2NNlxiIql
RT @tyabu7973: 急性感染症の入院患者に対するCFPM vs TAZ/PIPCの非盲検 RCT（ACORN）がJAMAに出てました。 14日までの急性腎障害や死亡の複合アウトカムは有意差なし。 副次アウトカムではCFPMの方がせん妄や昏睡などの神経障害が多い結果だっ…
RT @tyabu7973: 急性感染症の入院患者に対するCFPM vs TAZ/PIPCの非盲検 RCT（ACORN）がJAMAに出てました。 14日までの急性腎障害や死亡の複合アウトカムは有意差なし。 副次アウトカムではCFPMの方がせん妄や昏睡などの神経障害が多い結果だっ…
RT @tyabu7973: 急性感染症の入院患者に対するCFPM vs TAZ/PIPCの非盲検 RCT（ACORN）がJAMAに出てました。 14日までの急性腎障害や死亡の複合アウトカムは有意差なし。 副次アウトカムではCFPMの方がせん妄や昏睡などの神経障害が多い結果だっ…
RT @KBibbinsDomingo: Read the ACORN trial here #ESICM #LIVES2023 Cefepime vs Piperacillin-Tazobactam in Adults Hospitalized With Acute In…
RT @tyabu7973: 急性感染症の入院患者に対するCFPM vs TAZ/PIPCの非盲検 RCT（ACORN）がJAMAに出てました。 14日までの急性腎障害や死亡の複合アウトカムは有意差なし。 副次アウトカムではCFPMの方がせん妄や昏睡などの神経障害が多い結果だっ…
Now trending on the AMA Ed Hub: Cefepime vs Piperacillin-Tazobactam in Adults Hospitalized With Acute Infection https://t.co/Ux49aHbMAT #CME
RT @tyabu7973: 急性感染症の入院患者に対するCFPM vs TAZ/PIPCの非盲検 RCT（ACORN）がJAMAに出てました。 14日までの急性腎障害や死亡の複合アウトカムは有意差なし。 副次アウトカムではCFPMの方がせん妄や昏睡などの神経障害が多い結果だっ…
RT @tyabu7973: 急性感染症の入院患者に対するCFPM vs TAZ/PIPCの非盲検 RCT（ACORN）がJAMAに出てました。 14日までの急性腎障害や死亡の複合アウトカムは有意差なし。 副次アウトカムではCFPMの方がせん妄や昏睡などの神経障害が多い結果だっ…
急性感染症の入院患者に対するCFPM vs TAZ/PIPCの非盲検 RCT（ACORN）がJAMAに出てました。 14日までの急性腎障害や死亡の複合アウトカムは有意差なし。 副次アウトカムではCFPMの方がせん妄や昏睡などの神経障害が多い結果だった。 https://t.co/G8rWftOatA
RT @SCCM_CPP: @SCCM @KiousenterlisN @nyphospital @ATSBlueEditor #SCCMJC #PharmICU Presenter 2: Kacy Oldsen, PharmD @kacyoldsen PGY2 CC @My…
@SCCM @KiousenterlisN @nyphospital @ATSBlueEditor #SCCMJC #PharmICU Presenter 2: Kacy Oldsen, PharmD @kacyoldsen PGY2 CC @MyMemorial Cefepime vs Piperacillin-Tazobactam in Adults Hospitalized With Acute Infection (ACORN) @JAMA_current https://t.co/p2NNlxiIql
RT @KBibbinsDomingo: Top viewed this week at JAMA includes: 3️⃣ RCTs IV Vitamin C for COVID-19 @remap_cap https://t.co/c2lrZAyJfa Cefepi…
RT @KBibbinsDomingo: Top viewed this week at JAMA includes: 3️⃣ RCTs IV Vitamin C for COVID-19 @remap_cap https://t.co/c2lrZAyJfa Cefepi…
Top viewed this week at JAMA includes: 3️⃣ RCTs IV Vitamin C for COVID-19 @remap_cap https://t.co/c2lrZAyJfa Cefepime vs Pip-Taz in hospitalized patients https://t.co/LYL15f3W23 Traditional Chinese med Tongxinluo in patients with MI https://t.co/7yVMd65Zx1 https://t.co/LhkagxeaxD
RT @ryoma_tanaka: 「バンコマイシン＋ゾシンは腎臓に悪い」がすっかり定着してしまいましたが、セフェピンと比較してゾシンは急性腎傷害を増やさないという結果。 セフェピンでせん妄や昏睡といった神経合併症が増えるかも。 ACORN trial https://t…
RT @ATS_PITB: #ACORN trial results are out! Will this change your practice? Share your thoughts with the @ATS_PITB community! Cefepime vs…
RT @ryoma_tanaka: 「バンコマイシン＋ゾシンは腎臓に悪い」がすっかり定着してしまいましたが、セフェピンと比較してゾシンは急性腎傷害を増やさないという結果。 セフェピンでせん妄や昏睡といった神経合併症が増えるかも。 ACORN trial https://t…
RT @ryoma_tanaka: 「バンコマイシン＋ゾシンは腎臓に悪い」がすっかり定着してしまいましたが、セフェピンと比較してゾシンは急性腎傷害を増やさないという結果。 セフェピンでせん妄や昏睡といった神経合併症が増えるかも。 ACORN trial https://t…
RT @ryoma_tanaka: 「バンコマイシン＋ゾシンは腎臓に悪い」がすっかり定着してしまいましたが、セフェピンと比較してゾシンは急性腎傷害を増やさないという結果。 セフェピンでせん妄や昏睡といった神経合併症が増えるかも。 ACORN trial https://t…
Cefepime vs Piperacillin-Tazobactam in Adults Hospitalized With Acute Infection En pacientes hospitalizados el tratamiento con piper-tazo o cefepime no aumentó la incidencia de lesión renal aguda o muerte. Cefepime dio lugar a mayor disfunción neurológica https://t.co/sHS2D2qrfq
RT @ryoma_tanaka: 「バンコマイシン＋ゾシンは腎臓に悪い」がすっかり定着してしまいましたが、セフェピンと比較してゾシンは急性腎傷害を増やさないという結果。 セフェピンでせん妄や昏睡といった神経合併症が増えるかも。 ACORN trial https://t…
RT @ryoma_tanaka: 「バンコマイシン＋ゾシンは腎臓に悪い」がすっかり定着してしまいましたが、セフェピンと比較してゾシンは急性腎傷害を増やさないという結果。 セフェピンでせん妄や昏睡といった神経合併症が増えるかも。 ACORN trial https://t…
RT @ryoma_tanaka: 「バンコマイシン＋ゾシンは腎臓に悪い」がすっかり定着してしまいましたが、セフェピンと比較してゾシンは急性腎傷害を増やさないという結果。 セフェピンでせん妄や昏睡といった神経合併症が増えるかも。 ACORN trial https://t…
RT @ryoma_tanaka: 「バンコマイシン＋ゾシンは腎臓に悪い」がすっかり定着してしまいましたが、セフェピンと比較してゾシンは急性腎傷害を増やさないという結果。 セフェピンでせん妄や昏睡といった神経合併症が増えるかも。 ACORN trial https://t…
RT @ryoma_tanaka: 「バンコマイシン＋ゾシンは腎臓に悪い」がすっかり定着してしまいましたが、セフェピンと比較してゾシンは急性腎傷害を増やさないという結果。 セフェピンでせん妄や昏睡といった神経合併症が増えるかも。 ACORN trial https://t…
RT @ryoma_tanaka: 「バンコマイシン＋ゾシンは腎臓に悪い」がすっかり定着してしまいましたが、セフェピンと比較してゾシンは急性腎傷害を増やさないという結果。 セフェピンでせん妄や昏睡といった神経合併症が増えるかも。 ACORN trial https://t…
RT @ryoma_tanaka: 「バンコマイシン＋ゾシンは腎臓に悪い」がすっかり定着してしまいましたが、セフェピンと比較してゾシンは急性腎傷害を増やさないという結果。 セフェピンでせん妄や昏睡といった神経合併症が増えるかも。 ACORN trial https://t…
RT @ryoma_tanaka: 「バンコマイシン＋ゾシンは腎臓に悪い」がすっかり定着してしまいましたが、セフェピンと比較してゾシンは急性腎傷害を増やさないという結果。 セフェピンでせん妄や昏睡といった神経合併症が増えるかも。 ACORN trial https://t…
RT @ryoma_tanaka: 「バンコマイシン＋ゾシンは腎臓に悪い」がすっかり定着してしまいましたが、セフェピンと比較してゾシンは急性腎傷害を増やさないという結果。 セフェピンでせん妄や昏睡といった神経合併症が増えるかも。 ACORN trial https://t…
RT @ryoma_tanaka: 「バンコマイシン＋ゾシンは腎臓に悪い」がすっかり定着してしまいましたが、セフェピンと比較してゾシンは急性腎傷害を増やさないという結果。 セフェピンでせん妄や昏睡といった神経合併症が増えるかも。 ACORN trial https://t…
RT @PulmCrit: PIPERACILLIN-TAZOBACTAM IS NOT NEPHROTOXIC: exploring the arc of a myth over time this was clearly a myth in 2016: https://t…
RT @ryoma_tanaka: 「バンコマイシン＋ゾシンは腎臓に悪い」がすっかり定着してしまいましたが、セフェピンと比較してゾシンは急性腎傷害を増やさないという結果。 セフェピンでせん妄や昏睡といった神経合併症が増えるかも。 ACORN trial https://t…
RT @ryoma_tanaka: 「バンコマイシン＋ゾシンは腎臓に悪い」がすっかり定着してしまいましたが、セフェピンと比較してゾシンは急性腎傷害を増やさないという結果。 セフェピンでせん妄や昏睡といった神経合併症が増えるかも。 ACORN trial https://t…
RT @ryoma_tanaka: 「バンコマイシン＋ゾシンは腎臓に悪い」がすっかり定着してしまいましたが、セフェピンと比較してゾシンは急性腎傷害を増やさないという結果。 セフェピンでせん妄や昏睡といった神経合併症が増えるかも。 ACORN trial https://t…
RT @ryoma_tanaka: 「バンコマイシン＋ゾシンは腎臓に悪い」がすっかり定着してしまいましたが、セフェピンと比較してゾシンは急性腎傷害を増やさないという結果。 セフェピンでせん妄や昏睡といった神経合併症が増えるかも。 ACORN trial https://t…
RT @ryoma_tanaka: 「バンコマイシン＋ゾシンは腎臓に悪い」がすっかり定着してしまいましたが、セフェピンと比較してゾシンは急性腎傷害を増やさないという結果。 セフェピンでせん妄や昏睡といった神経合併症が増えるかも。 ACORN trial https://t…
RT @ryoma_tanaka: 「バンコマイシン＋ゾシンは腎臓に悪い」がすっかり定着してしまいましたが、セフェピンと比較してゾシンは急性腎傷害を増やさないという結果。 セフェピンでせん妄や昏睡といった神経合併症が増えるかも。 ACORN trial https://t…
「バンコマイシン＋ゾシンは腎臓に悪い」がすっかり定着してしまいましたが、セフェピンと比較してゾシンは急性腎傷害を増やさないという結果。 セフェピンでせん妄や昏睡といった神経合併症が増えるかも。 ACORN trial https://t.co/OjA2BmNSW9
RT @PulmCrit: PIPERACILLIN-TAZOBACTAM IS NOT NEPHROTOXIC: exploring the arc of a myth over time this was clearly a myth in 2016: https://t…
RT @KBibbinsDomingo: Most viewed in JAMA in last 7 days? 1️⃣-2nd week in a row Cefepime vs Piperacillin-Tazobactam in Adults Hospitalized…
RT @brainicudoc: Cefepime vs Piperacillin-Tazobactam in Adults Hospitalized With Acute Infection: The ACORN Randomized Clinical Trial | Cri…
RT @KBibbinsDomingo: Most viewed in JAMA in last 7 days? 1️⃣-2nd week in a row Cefepime vs Piperacillin-Tazobactam in Adults Hospitalized…
Most viewed in JAMA in last 7 days? 1️⃣-2nd week in a row Cefepime vs Piperacillin-Tazobactam in Adults Hospitalized With Acute Infection: ACORN RCT -Edward Qian et al jamanetwork.com/journals/jam... Presented #IDWeek Editorial jamanetwork.com/journals/jam... #criticalcare #ID
RT @KBibbinsDomingo: Most viewed in JAMA in last 7 days? 1️⃣-2nd week in a row Cefepime vs Piperacillin-Tazobactam in Adults Hospitalized…
RT @KBibbinsDomingo: Most viewed in JAMA in last 7 days? 1️⃣-2nd week in a row Cefepime vs Piperacillin-Tazobactam in Adults Hospitalized…
Most viewed in JAMA in last 7 days? 1️⃣-2nd week in a row Cefepime vs Piperacillin-Tazobactam in Adults Hospitalized With Acute Infection: ACORN RCT @EdQian @toddrice_ICU et al https://t.co/LYL15f3ocv Presented #IDWeek @IDSAInfo Editorial https://t.co/Rt8Y1rpdfH #criticalcare https://t.co/WHlPrjtI4S
Cefepime vs Piperacillin-Tazobactam in Adults Hospitalized With Acute Infection The study determines the risks of acute kidney injury or neurological dysfunction. Cefepime resulted in more neurological dysfunction. #medicine #antibiotics #JAMA https://t.co/bxuGDzXYK8
Cefepime vs Piperacillin-Tazobactam in Adults Hospitalized With Acute Infection https://t.co/cdFEbNBw55
RT @ABsteward:
Cefepime vs Piperacillin-Tazobactam in Adults Hospitalized With Acute Infection: The ACORN Randomized Clinical Trial | Critical Care Medicine | JAMA | JAMA Network https://t.co/5rhd7gmm4Q
RT @tscquizzato: Now @EdQian presenting the second-last trial of the President’s session: Clinical trials in Intensive Care chaired by @Eli…
RT @ABsteward:
RT @ABsteward:
Cefepime vs Piperacillin-Tazobactam in Adults Hospitalized With Acute Infection https://t.co/0Zw8q5AAEP
Cefepime vs Piperacillin-Tazobactam in Adults Hospitalized With Acute Infection https://t.co/ugMRTXZmcX https://t.co/894yiVM1zS
RT @tscquizzato: Now @EdQian presenting the second-last trial of the President’s session: Clinical trials in Intensive Care chaired by @Eli…
RT @tscquizzato: Now @EdQian presenting the second-last trial of the President’s session: Clinical trials in Intensive Care chaired by @Eli…
RT @KBibbinsDomingo: Dr Edward Qian @EdQian presents in the @ESICM Opening President’s Session #LIVES2023 the results of ACORN published la…
RT @KBibbinsDomingo: Dr Edward Qian @EdQian presents in the @ESICM Opening President’s Session #LIVES2023 the results of ACORN published la…
RT @tscquizzato: Now @EdQian presenting the second-last trial of the President’s session: Clinical trials in Intensive Care chaired by @Eli…
RT @JAMA_current: Just presented in the #LIVES2023 Presidents' Session: Cefepime vs Piperacillin-Tazobactam in Adults Hospitalized With Acu…
RT @KBibbinsDomingo: Dr Edward Qian @EdQian presents in the @ESICM Opening President’s Session #LIVES2023 the results of ACORN published la…
RT @JAMA_current: Just presented in the #LIVES2023 Presidents' Session: Cefepime vs Piperacillin-Tazobactam in Adults Hospitalized With Acu…
Dr Edward Qian presents in the ESICM Opening President’s Session #LIVES2023 the results of ACORN published last week in JAMA Cefepime vs Piperacillin-Tazobactam in Adults Hospitalized With Acute Infection: The ACORN Randomized Clinical Trial jamanetwork.com/journals/jama/…
RT @KBibbinsDomingo: Dr Edward Qian @EdQian presents in the @ESICM Opening President’s Session #LIVES2023 the results of ACORN published la…
RT @tscquizzato: Now @EdQian presenting the second-last trial of the President’s session: Clinical trials in Intensive Care chaired by @Eli…
RT @tscquizzato: Now @EdQian presenting the second-last trial of the President’s session: Clinical trials in Intensive Care chaired by @Eli…
RT @KBibbinsDomingo: Dr Edward Qian @EdQian presents in the @ESICM Opening President’s Session #LIVES2023 the results of ACORN published la…
RT @JAMA_current: Just presented in the #LIVES2023 Presidents' Session: Cefepime vs Piperacillin-Tazobactam in Adults Hospitalized With Acu…
RT @JAMANetwork: Just presented in the #LIVES2023 Presidents' Session: Cefepime vs Piperacillin-Tazobactam in Adults Hospitalized With Acut…
RT @tscquizzato: Now @EdQian presenting the second-last trial of the President’s session: Clinical trials in Intensive Care chaired by @Eli…
Just presented in the #LIVES2023 Presidents' Session: Cefepime vs Piperacillin-Tazobactam in Adults Hospitalized With Acute Infection: The ACORN Randomized Clinical Trial, from @JAMA_current, free to read online https://t.co/Hm8qLoJCUq https://t.co/aScMrjfqHP
Just presented in the #LIVES2023 Presidents' Session: Cefepime vs Piperacillin-Tazobactam in Adults Hospitalized With Acute Infection: The ACORN Randomized Clinical Trial, from JAMA, free to read online https://t.co/lg3noPXBwM https://t.co/UFZhzIX7V0
RT @KBibbinsDomingo: Dr Edward Qian @EdQian presents in the @ESICM Opening President’s Session #LIVES2023 the results of ACORN published la…
RT @KBibbinsDomingo: Dr Edward Qian @EdQian presents in the @ESICM Opening President’s Session #LIVES2023 the results of ACORN published la…
RT @KBibbinsDomingo: Dr Edward Qian @EdQian presents in the @ESICM Opening President’s Session #LIVES2023 the results of ACORN published la…
Read the ACORN trial here #ESICM #LIVES2023 Cefepime vs Piperacillin-Tazobactam in Adults Hospitalized With Acute Infection: The ACORN Randomized Clinical Trial https://t.co/xA5SHNamml https://t.co/tJzIGuar5F
Dr Edward Qian @EdQian presents in the @ESICM Opening President’s Session #LIVES2023 the results of ACORN published last week in JAMA @JAMA_current Cefepime vs Piperacillin-Tazobactam in Adults Hospitalized With Acute Infection: The ACORN Randomized Clinical Trial https://t.co/zo2ws9Zqhk
RT @tscquizzato: Now @EdQian presenting the second-last trial of the President’s session: Clinical trials in Intensive Care chaired by @Eli…
Now @EdQian presenting the second-last trial of the President’s session: Clinical trials in Intensive Care chaired by @ElieAzoulay5 @criticcaredoc The #ACORNtrial: Cefepime vs Piperacillin-Tazobactam in Adults Hospitalized With Acute Infection Published recently in https://t.co/h25OarvcFT
RT @pinacol: 【RCT】救急部またはICUで感染症が疑われた患者への症状提示12時間以内のピペラシリン-タゾバクタムの投与は、セフェピムの投与と比較して、ステージ3のAKIや死亡を増加させなかった。 #ペ読 https://t.co/hA0Lc3h7at
Things I learned halfway through my PGY-27 year, cefepime has ⬆️ risk neuro dysfunction Cefepime vs Piperacillin-Tazobactam in Adults Hospitalized With Acute Infection: The ACORN Randomized Clinical Trial | Critical Care Medicine | JAMA | JAMA Network https://t.co/VjvVfB0Xi9
Trending on PubMed: Cefepime vs Piperacillin-Tazobactam in Adults Hospitalized With Acute Infection: The ACORN Randomized Clinical Trial. https://t.co/EJjgfAFHU2
RT @ABsteward:
【RCT】救急部またはICUで感染症が疑われた患者への症状提示12時間以内のピペラシリン-タゾバクタムの投与は、セフェピムの投与と比較して、ステージ3のAKIや死亡を増加させなかった。 #ペ読 https://t.co/hA0Lc3h7at
RT @ABsteward:
Top 5️⃣ viewed articles in JAMA in the last 7 days? 1️⃣ Cefepime vs Piperacillin-Tazobactam in Adults Hospitalized With Acute Infection: The ACORN Randomized Clinical Trial #MedSky jamanetwork.com/journals/jama/…
RT @JonathanNefro: Las personas que reciben Piperacilina/tazobactam tuvieron la misma Incidencia de lesión renal aguda o algún evento rena…
RT @JonathanNefro: Las personas que reciben Piperacilina/tazobactam tuvieron la misma Incidencia de lesión renal aguda o algún evento rena…
RT @JonathanNefro: Las personas que reciben Piperacilina/tazobactam tuvieron la misma Incidencia de lesión renal aguda o algún evento rena…
RT @JonathanNefro: Las personas que reciben Piperacilina/tazobactam tuvieron la misma Incidencia de lesión renal aguda o algún evento rena…
RT @JonathanNefro: Las personas que reciben Piperacilina/tazobactam tuvieron la misma Incidencia de lesión renal aguda o algún evento rena…
RT @JonathanNefro: Las personas que reciben Piperacilina/tazobactam tuvieron la misma Incidencia de lesión renal aguda o algún evento rena…
RT @JonathanNefro: Las personas que reciben Piperacilina/tazobactam tuvieron la misma Incidencia de lesión renal aguda o algún evento rena…
RT @JonathanNefro: Las personas que reciben Piperacilina/tazobactam tuvieron la misma Incidencia de lesión renal aguda o algún evento rena…
RT @JonathanNefro: Las personas que reciben Piperacilina/tazobactam tuvieron la misma Incidencia de lesión renal aguda o algún evento rena…
RT @JonathanNefro: Las personas que reciben Piperacilina/tazobactam tuvieron la misma Incidencia de lesión renal aguda o algún evento rena…
RT @JonathanNefro: Las personas que reciben Piperacilina/tazobactam tuvieron la misma Incidencia de lesión renal aguda o algún evento rena…
RT @JonathanNefro: Las personas que reciben Piperacilina/tazobactam tuvieron la misma Incidencia de lesión renal aguda o algún evento rena…
RT @JonathanNefro: Las personas que reciben Piperacilina/tazobactam tuvieron la misma Incidencia de lesión renal aguda o algún evento rena…
RT @JonathanNefro: Las personas que reciben Piperacilina/tazobactam tuvieron la misma Incidencia de lesión renal aguda o algún evento rena…
RT @JonathanNefro: Las personas que reciben Piperacilina/tazobactam tuvieron la misma Incidencia de lesión renal aguda o algún evento rena…
RT @JonathanNefro: Las personas que reciben Piperacilina/tazobactam tuvieron la misma Incidencia de lesión renal aguda o algún evento rena…
RT @JonathanNefro: Las personas que reciben Piperacilina/tazobactam tuvieron la misma Incidencia de lesión renal aguda o algún evento rena…
RT @JonathanNefro: Las personas que reciben Piperacilina/tazobactam tuvieron la misma Incidencia de lesión renal aguda o algún evento rena…
RT @JonathanNefro: Las personas que reciben Piperacilina/tazobactam tuvieron la misma Incidencia de lesión renal aguda o algún evento rena…
RT @JonathanNefro: Las personas que reciben Piperacilina/tazobactam tuvieron la misma Incidencia de lesión renal aguda o algún evento rena…
RT @JonathanNefro: Las personas que reciben Piperacilina/tazobactam tuvieron la misma Incidencia de lesión renal aguda o algún evento rena…
Las personas que reciben Piperacilina/tazobactam tuvieron la misma Incidencia de lesión renal aguda o algún evento renal mayor (~25%), al comparar con cefepime. Este último tuvo mayores complicaciones neurológicas En ensayo clínico #ISNyoung JAMA 2023 10.1001/jama.2023.20583 https://t.co/xqYoKtRnek
https://t.co/Elw7m9Wvaa
Cefepime vs Piperacillin-Tazobactam in Adults Hospitalized With Acute Infection: The ACORN Randomized Clinical Trial https://t.co/hOB6Xmu8lo https://t.co/S0R0VgAyak
Cefepime vs Piperacillin-Tazobactam in Adults Hospitalized With Acute Infection “The ACORN RCT” jamanetwork.com/journals/jam...
Hot off the press! PTZ nephrotoxicity debunked!
https://jamanetwork.com/journals/jama/fullarticle/2810592?guestAccessKey=8ff7f3d0-7224-4573-9d73-39b86c6de781&utm_source=twitter&utm_medium=social_jama&utm_term=11553296986&utm_campaign=article_alert&linkId=241365055
Just published online first in JAMA & presented #IDWeek2023 Cefepime vs Piperacillin-Tazobactam in Adults Hospitalized With Acute Infection: The ACORN Randomized Clinical Trial jamanetwork.com/journals/jam...
Original study DOI: 10.1001/jama.2023.20583 TBL: https://www.thebottomline.org.uk/summaries/icm/acorn/ Rebel EM: https://rebelem.com/the-acorn-trial ...
... 10.1001/jama.2023.20583 TBL: https://www.thebottomline.org.uk/summaries/icm/acorn/ Rebel EM: https://rebelem.com/the-acorn-trial-battle-of-the ...
... 10.1001/jama.2023.20583 TBL: https://www.thebottomline.org.uk/summaries/icm/acorn/ Rebel EM: https://rebelem.com/the-acorn-trial-battle-of-the ...
Original study DOI: 10.1001/jama.2023.20583 TBL: https://www.thebottomline.org.uk/summaries/icm/acorn/ Rebel EM: https://rebelem.com/the-acorn-trial ...
... 10.1001/jama.2023.20583 TBL: https://www.thebottomline.org.uk/summaries/icm/acorn/ Rebel EM: https://rebelem.com/the-acorn-trial-battle-of-the ...
... 10.1001/jama.2023.20583 TBL: https://www.thebottomline.org.uk/summaries/icm/acorn/ Rebel EM: https://rebelem.com/the-acorn-trial-battle-of-the ...
Original study DOI: 10.1001/jama.2023.20583 TBL: https://www.thebottomline.org.uk/summaries/icm/acorn/ Rebel EM: https://rebelem.com/the-acorn-trial ...
Original study DOI: 10.1001/jama.2023.20583 TBL: https://www.thebottomline.org.uk/summaries/icm/acorn/ Rebel EM: https://rebelem.com/the-acorn-trial ...
Original study DOI: 10.1001/jama.2023.20583 TBL: https://www.thebottomline.org.uk/summaries/icm/acorn/ Rebel EM: https://rebelem.com/the-acorn-trial ...
Original study DOI: 10.1001/jama.2023.20583 TBL: https://www.thebottomline.org.uk/summaries/icm/acorn/ Rebel EM: https://rebelem.com/the-acorn-trial ...
... 10.1001/jama.2023.20583 TBL: https://www.thebottomline.org.uk/summaries/icm/acorn/ Rebel EM: https://rebelem.com/the-acorn-trial-battle-of-the ...
Original study DOI: 10.1001/jama.2023.20583 TBL: https://www.thebottomline.org.uk/summaries/icm/acorn/ Rebel EM: https://rebelem.com/the-acorn-trial ...
JAMA. 2025;333(10):875-890. doi: 10.1001/jama.2024.26244. Guan L, Niu J, Huang Q, et al. High-flow nasal oxygen therapy in patients with hypercapnic ...
JAMA. 2023;330(16):1557-1567. doi:10.1001/ (8):801-810. doi:10.1001/jama.2016.0287 urinary tract infection in adults: 2009 international jama.2023.20583 2 ...
JAMA. 2023;330(16):1557-1567. doi:10.1001/jama.2023.20583 (christopher.seymour@jamanetwork. Published online October 14, ...
JAMA; Funder: NIH/National Heart, Lung and Blood Institute; DOI: 10.1001/jama.2023.20583. Keywords. /Health and medicine/Clinical medicine/Medical treatments ...
JAMA; Funder: NIH/National Heart, Lung and Blood Institute; DOI: 10.1001/jama.2023.20583. Keywords. /Health and medicine/Clinical medicine/Medical treatments ...
... ACORN Randomized Clinical Trial. JAMA. 2023 Oct 24;330(16):1557-1567. doi: 10.1001/jama.2023.20583. Share Facebook LinkedIn X Copy Link Print Email ...
... 10.1001/jama.2025.21056 AHAScience: https://www.youtube.com/watch ... 2023.20583 TBL: https://www.thebottomline.org.uk/summaries ...
Original study DOI: 10.1001/jama.2023.20583 TBL: https://www.thebottomline.org.uk/summaries/icm/acorn/ Rebel EM: https://rebelem.com ...
... 10.1001/jama.2023.20583 TBL: https://www.thebottomline.org.uk/summaries/icm/acorn/ Rebel EM: https://rebelem.com/the-acorn-trial-battle ...
... 10.1001/jama.2023.20583 TBL: https://www.thebottomline.org.uk/summaries/icm/acorn/ Rebel EM: https://rebelem.com/the-acorn-trial-battle ...
... 10.1001/jama.2023.20583 TBL: https://www.thebottomline.org.uk/summaries/icm/acorn/ Rebel EM: https://rebelem.com/the-acorn-trial-battle ...
... 10.1001/jama.2023.20583 TBL: https://www.thebottomline.org.uk/summaries/icm/acorn/ Rebel EM: https://rebelem.com/the-acorn-trial-battle ...
... 10.1001/jama.2023.20583 TBL: https://www.thebottomline.org.uk/summaries/icm/acorn/ Rebel EM: https://rebelem.com/the-acorn-trial-battle ...
... 10.1001/jama.2025.21056 AHAScience: https://www.youtube.com/watch ... 2023.20583 TBL: https://www.thebottomline.org.uk/summaries ...
... 10.1001/jama.2023.20583 TBL: https://www.thebottomline.org.uk/summaries/icm/acorn/ Rebel EM: https://rebelem.com/the-acorn-trial-battle ...
... 10.1001/jama.2025.21056 AHAScience: https://www.youtube.com/watch ... 2023.20583 TBL: https://www.thebottomline.org.uk/summaries ...
... 10.1001/jama.2023.20583 TBL: https://www.thebottomline.org.uk/summaries/icm/acorn/ Rebel EM: https://rebelem.com/the-acorn-trial-battle ...
JAMA. 2023;330(16):1557–1567. doi:10.1001/jama.2023.20583. More AKIs with Zosyn than cefepime or mero Blevins AM, Lashinsky JN, McCammon C ...
... 10.1001/jama.2023.20583 TBL: https://www.thebottomline.org.uk/summaries/icm/acorn/ Rebel EM: https://rebelem.com/the-acorn-trial-battle ...
... 10.1001/jama.2023.20583 TBL: https://www.thebottomline.org.uk/summaries/icm/acorn/ Rebel EM: https://rebelem.com/the-acorn-trial-battle ...
... 10.1001/jama.2025.21056 AHAScience: https://www.youtube.com/watch ... 2023.20583 TBL: https://www.thebottomline.org.uk/summaries ...
... 10.1001/jama.2023.20583 TBL: https://www.thebottomline.org.uk/summaries/icm/acorn/ Rebel EM: https://rebelem.com/the-acorn-trial-battle ...
DOI: 10.1001/jama.2023.20583. 更多. 查看1 条评论. 4月13日 · wakeforestemresidency的头像. wakeforestemresidency. •. 关注.
DOI: 10.1001/jama.2023.20583. more. View 1 comment. April 13 · wakeforestemresidency's profile picture. wakeforestemresidency. •. Follow.
Jama. 2023;330(16):1557–67. https://doi.org/10.1001/jama.2023.20583. 9. Dequin PF, Meziani F, Quenot JP, et al. Hydrocortisone in severe ...
... 10.1001/jama.2023.20583 TBL: https://www.thebottomline.org.uk/summaries/icm/acorn/ Rebel EM: https://rebelem.com/the-acorn-trial-battle ...
... 10.1001/jama.2023.20583. more. View 1 comment. April 13 · Sign up • Instagram · Meta · About · Blog · Jobs · Help · API · Privacy · Consumer ...
JAMA 2023; 330:1557–1567. doi: 10.1001/jama.2023.20583. PubMed. Qian ET , ; Vanderbilt Center for Learning Healthcare and the Pragmatic ...
... Randomized Clinical Trial. JAMA. 2023 Oct 24;330(16):1557-1567. doi: 10.1001/jama.2023.20583. Share Facebook LinkedIn X Copy Link Print Email.
Cefepime vs Piperacillin-Tazobactam in Adults Hospitalized With Acute Infection. Qian ET. JAMA 2023;330:1557-1567. doi:10.1001/jama.2023.20583 ...
... piperacillin-tazobactam and cefepime should be carefully weighed. JAMA. 2023;330(16):1557-1567. doi:10.1001/jama.2023.20583.
DOI: 10.1001/jama.2023.20583. more. View 1 comment. April 13 · Sign up • Instagram · Meta · About · Blog · Jobs · Help · API · Privacy.
2023 Oct 14:e2320583. doi: 10.1001/jama.2023.20583. Online ahead of print.
DOI: 10.1001/jama.2023.20583. more. View 1 comment. April 13 · Sign up • Instagram · Meta · About · Blog · Jobs · Help · API · Privacy.
Das zeigt die randomisiert-kontrollierte Studie ACORN, deren Ergebnisse jetzt in JAMA veröffentlicht wurden (2023; DOI: 10.1001/jama.2023.20583) ...
... JAMA 2023; DOI: 10.1001/jama.2023.20583. Secondary Source. JAMA. Source Reference: Tong SYC, et al "Acute kidney injury with empirical ...
JAMA; Funder: NIH/National Heart, Lung and Blood Institute; DOI: 10.1001/jama.2023.20583. Keywords. /Health and medicine/Clinical medicine/ ...
JAMA. doi.org/10.1001/jama.2023.20583. Be the first to rate this article. Posted in: Drug Trial News | Medical Condition News. Comments (0).
(doi:10.1001/jama.2023.20583). Editor's Note: Please see the article ... jama/fullarticle/10.1001/jama.2023.20583?guestAccessKey ...
Among hospitalized adults, the risk of acute kidney injury did not differ between cefepime and piperacillin-tazobactam, but neurological ...
DOI: 10.1001/jama.2023.20583. more. View 1 comment. April 13 · Sign up • Instagram · Meta · About · Blog · Jobs · Help · API · Privacy.
DOI: 10.1001/jama.2023.20583. more. View 1 comment. April 13 · Sign up • Instagram · Meta · About · Blog · Jobs · Help · API · Privacy.
DOI: 10.1001/jama.2023.20583. more. View 1 comment. April 13 · Sign up • Instagram · Meta · About · Blog · Jobs · Help · API · Privacy.
Original study DOI: 10.1001/jama.2023.20583 TBL: https://www.thebottomline.org.uk/summaries/icm/acorn/ Rebel EM: https://rebelem.com ...
DOI: 10.1001/jama.2023.20583. 更多. 查看1 条评论. 4月13日 · wakeforestemresidency的头像 · wakeforestemresidency. •. 关注.
... 10.1001/jama.2023.20583 TBL: https://www.thebottomline.org.uk/summaries/icm/acorn/ Rebel EM: https://rebelem.com/the-acorn-trial-battle ...
DOI: 10.1001/jama.2023.20583. more. View 1 comment. April 13 · Sign up • Instagram · Meta · About · Blog · Jobs · Help · API · Privacy.
... 10.1001/jama.2023.20583 TBL: https://www.thebottomline.org.uk/summaries/icm/acorn/ Rebel EM: https://rebelem.com/the-acorn-trial-battle ...
DOI: 10.1001/jama.2023.20583. more. View 1 comment. April 13 · wakeforestemresidency's profile picture · wakeforestemresidency. •. Follow.
... 10.1001/jama.2023.20583 TBL: https://www.thebottomline.org.uk/summaries/icm/acorn/ Rebel EM: https://rebelem.com/the-acorn-trial-battle ...
DOI: 10.1001/jama.2023.20583. 更多. 查看1 条评论. 4月13日 · wakeforestemresidency的头像 · wakeforestemresidency. •. 关注.
DOI: 10.1001/jama.2023.20583. more. View 1 comment. April 13 · Sign up • Instagram · Meta · About · Blog · Jobs · Help · API · Privacy.
DOI: 10.1001/jama.2023.20583. more. View 1 comment. April 13 · Sign up • Instagram · Meta · About · Blog · Jobs · Help · API · Privacy.
DOI: 10.1001/jama.2023.20583. more. View 1 comment. April 13 · Sign up • Instagram · Meta · About · Blog · Jobs · Help · API · Privacy.
... 10.1001/jama.2023.20583 TBL: https://www.thebottomline.org.uk/summaries/icm/acorn/ Rebel EM: https://rebelem.com/the-acorn-trial-battle ...
田
森
JC
矢Y
JM
ち
A
X
CC
PM
MT
DZ
SA
MP
RP
SS
ME
PM
AG
C
シ
SK
A
?
T
KM
M
TK
WO
お
LR
G
AM
A
JK
DV
AK
MM
MS
FS
TL
PM
PL
SM
AF
RM
MH
T
TB
JH
GT
AD
RB
AF
TS
AM
MH
JF
AP
SU
AH
PM
DV
CS
SA
TR
SN
TL
R
NA
SS
Y
B
NB
AM
ME
EQ
KD
SS
H
MB
MJ
KM
LM
PP
I
AG
CP
BA
AP
PC
KT
A
C
R
JR
AH
SD
RB
TP
AL
と
な
D
P
智
大
KP
MB
J
高哲
AC
え
MS
晒
SC
バ内
さ
抗
E
G
み
SM
A
で
A
な
YD
から
S
AF
A
AW
DD
BM
AA
AM
MV
BP
แว
UR
S
AR
PS
GM
小P
AO
M
J
KD
GT
AS
JN
GM
TM
JM
BC
PT
SB
P
MA
LS
AA
H
RV
DC
MB
D
M
PO
C
M
C
RM
D
LD
EA
DL
P
DN
BD
FM
R
AL